Fear of Cancer Recurrence Persists in Long-Term Survivors, Systematic Review Finds

Fear of cancer recurrence (FCR) is one of the most frequently reported psychological challenges faced by people who have been treated for cancer, and a new systematic review suggests that this fear does not simply fade with time. Published in Supportive Care in Cancer, the review by Conor Wheeler of NHS Greater Glasgow and Clyde and Noelle O’Rourke of the Beatson West of Scotland Cancer Centre set out to answer a deceptively simple question: how common is clinically significant fear of recurrence among survivors who are more than five years past their diagnosis? The answer matters because the majority of FCR research has concentrated on patients during or shortly after treatment, leaving the long-term survivorship period comparatively underexplored even as the global population of cancer survivors continues to grow.

The researchers applied PRISMA methodology, the internationally recognised reporting standard for systematic reviews, to identify studies that assessed FCR in survivors beyond the five-year mark. Their search strategy, constructed with the help of a senior librarian at the Beatson Cancer Centre, spanned three major bibliographic databases: Ovid MEDLINE from 1946 to June 2025, APA PsycInfo from 2002 to late June 2025, and Embase from 1974 to June 2025. The searches combined controlled vocabulary terms for neoplasm recurrence and fear with text-word phrases capturing expressions such as fear, worry, or anxiety paired with recurrence, return, or the cancer coming back. Publications were limited to those published between 2005 and 2025, and the reviewers applied strict inclusion criteria: studies had to use validated assessment measures, include more than 50 participants, and report FCR in survivors at least five years from diagnosis.

Two authors independently screened the search output for eligibility, a standard safeguard against selection bias in systematic reviews. Data extraction recorded the number of participants, tumour type, study design, the FCR measurement tool used, the time points at which fear was assessed, and the reported prevalence. Risk of bias was formally assessed to address study quality, allowing the reviewers to distinguish findings from more robust studies from those with methodological weaknesses. This structured approach reflects guidance for systematic reviews of observational studies reporting prevalence data, which emphasises transparent eligibility criteria and independent assessment as core quality controls.

From the extensive search, ten papers met the inclusion criteria. These studies reported FCR measurements taken anywhere from five years to beyond twenty years after diagnosis, covering a heterogeneous mix of tumour types and patient ages. Sample sizes ranged considerably, from as few as 64 participants to as many as 5,983, illustrating the wide variation in scale across the long-term survivorship literature. Only two of the included studies reported longitudinal measurements, meaning they tracked the same patients over time; the remainder were cross-sectional, capturing a single snapshot of fear at one point in survivorship. This scarcity of longitudinal data is a significant limitation, because cross-sectional designs cannot show whether fear rises, falls, or remains stable within individuals as the years pass.

The methodological consistency of the included studies was narrow. Only two validated instruments appeared across the ten papers: the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) and the Fear of Progression Questionnaire-Short Form (FOP-Q-SF). The FCRI, originally developed and validated by Simard and Savard, is a multidimensional measure of FCR, and its short form has been evaluated for its capacity to screen for clinical levels of fear. The FOP-Q, developed by Herschbach and colleagues, was designed to measure fear of progression in chronic diseases more broadly and has been applied to cancer-related progression fears in breast cancer survivors. The reliance on just two tools across the review underscores both the strength of standardisation in this subset of studies and the wider fragmentation of FCR measurement in the field, where numerous instruments, including the Cancer Worry Scale, the Concerns About Recurrence Scale, and single-item screening measures, have been used in different studies.

The headline finding concerns prevalence. Among the studies judged to have acceptable risk of bias and reporting distinct cohorts beyond five years, the prevalence of FCR above defined clinical thresholds ranged from 13 to 33.9 percent. In other words, between roughly one in eight and one in three long-term survivors experienced fear of recurrence at a level considered clinically relevant, years or even decades after their original diagnosis. This range, while broad, is consistent with the picture emerging from a large individual participant data meta-analysis published in 2022, which examined FCR prevalence across cancer survivors and patients more generally and found that a substantial minority experience high fear. The consistency of elevated prevalence at the five-year mark and beyond challenges any assumption that psychological adjustment follows a simple trajectory of steady improvement after treatment ends.

The review’s conclusions carry clinical weight. The authors state that the limited evidence suggests clinically relevant FCR persists in some survivors at five years, and they argue that this persistence demands attention from clinicians and health services. FCR is not a trivial concern: research has linked it to psychological distress, impaired quality of life, and altered health behaviours, and a 2025 survey-administrative data linkage study found that fear of cancer recurrence is associated with higher primary care use after cancer treatment. Persistent fear may also drive repeated reassurance-seeking, over-monitoring, or avoidance of follow-up appointments, each with implications for both patient wellbeing and health system resources. The authors highlight the need to implement effective interventions for those whose fear remains clinically significant long after treatment.

Fortunately, the intervention evidence base has been growing. A 2019 meta-analysis published in the Journal of Clinical Oncology found that psychological interventions can reduce FCR, and randomised controlled trials such as ConquerFear, a theoretically based psychosocial intervention tested in a randomised trial reported in 2017, have demonstrated benefits for survivors with high fear. Adaptations of approaches such as Mindful Self-Compassion have been explored for feasibility and acceptability in cancer populations, and novel interventions, including written exposure to worst-case scenarios for patients with advanced disease, are under investigation. A virtual version of Family Caregiver-Fear Of Recurrence Therapy has been developed to address fear in family caregivers, recognising that FCR affects the wider support network. However, most intervention trials have focused on patients earlier in the survivorship trajectory, and the new review’s findings raise the question of whether long-term survivors with persistent fear can access and benefit from these evidence-based treatments.

Beyond the headline prevalence figures, the review exposes deeper structural problems in FCR research. The heterogeneity of patient populations across the included studies, spanning different tumour types, ages, and time points from five to more than twenty years post-diagnosis, makes it difficult to draw precise conclusions about who is most at risk or how prevalence changes over time. The authors emphasise the need for improved consensus on measurement approaches, so that future studies produce comparable rather than fragmented data. They also call for more prospective longitudinal research representing a comprehensive variety of tumour types, which would allow researchers to map the natural course of fear over decades and identify the points at which intervention might be most effective. Such studies are resource-intensive but essential for building a genuinely developmental understanding of FCR across the survivorship trajectory.

The review arrives at a moment when cancer survivorship is gaining formal recognition in health policy. Expert consensus statements from the European Society for Medical Oncology have promoted high-quality survivorship care and research in Europe, and national cancer survivorship standards have been developed in the United States using consensus approaches. Survivorship science has been a growing focus at the National Institutes of Health, with dedicated analyses of funded grants in recent years. Against this backdrop, the finding that a meaningful proportion of survivors remain troubled by fear of recurrence five years and beyond provides a concrete evidence point for advocates arguing that survivorship care should include routine psychological assessment and access to targeted interventions, not just in the first year after diagnosis but throughout the long-term follow-up period. As the population of long-term survivors expands with improving cancer outcomes, understanding and addressing the persistent psychological footprint of cancer will become an increasingly central task for oncology.

Subject of Research: Prevalence of fear of cancer recurrence in long-term cancer survivors beyond five years

Article Title: How prevalent is fear of cancer recurrence beyond 5 years: a systematic review of validated assessments across tumour types

Article References: Wheeler, C., & O’Rourke, N. (2026). How prevalent is fear of cancer recurrence beyond 5 years: a systematic review of validated assessments across tumour types. Supportive Care in Cancer, 34(10), Article 936. https://doi.org/10.1007/s00520-026-11180-1

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11180-1

Keywords: fear of cancer recurrence, cancer survivors, systematic review, survivorship, psychological distress, long-term follow-up, FCRI-SF, FOP-Q-SF, prevalence, PRISMA, supportive care, psycho-oncology